Antipsychotic Polypharmacy Among Patients With Schizophrenia in Africa: A Systematic Review and Meta-Analysis

被引:10
|
作者
Ayenew, Wondim [1 ]
Asmamaw, Getahun [2 ]
Bitew, Teshome [3 ]
机构
[1] Univ Gondar, Coll Med & Hlth Sci, Sch Pharm, Dept Pharmaceut, POB 196, Gondar, Ethiopia
[2] Arba Minch Univ, Coll Med & Hlth Sci, Dept Pharm, Arba Minch, Ethiopia
[3] Pawe Hlth Sci Coll, Dept Pharm, Pawe, Ethiopia
来源
关键词
Africa; antipsychotic polypharmacy; antipsychotic prescribing; correlates of antipsychotic polypharmacy; prevalence; LONG-ACTING INJECTIONS; PSYCHIATRIC-PATIENTS; PREVALENCE; ADOLESCENTS; OUTPATIENTS; CHILDREN; 2ND-GENERATION; PRESCRIPTION; TRENDS; DRUGS;
D O I
10.1093/ijnp/pyab046
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: In Africa, antipsychotic polypharmacy (APP) is increasing due to a high antipsychotic dose prescribing, repeated psychiatric hospitalization, uncontrolled psychotic symptoms, and greater side effect burden. Therefore, the aim of this review and meta-analysis is to assess the prevalence and correlates of APP among patients with schizophrenia in Africa. Methods: A systematic search was performed from August 1 to 31, 2020, on PubMed, MEDLINE, Google Scholar, and Science Direct databases to select articles based on the inclusion criteria. Meta-Analysis of Observational studies in Epidemiology guidelines were employed. Cross-sectional observational studies that reported APP and/or its correlates in schizophrenia patients in English language published in peer-reviewed journals without time limits were included in the review. The quality of included articles was assessed using Newcastle-Ottawa quality assessment tool. Prevalence and correlates of APP were the outcome measures of this review and meta-analysis. Open Meta Analyst and RevMan version 5.3 software were used for meta-analysis. A random effect model was used to synthesize data based on the heterogeneity test. Results: Six studies that involved 2154 schizophrenia patients met the inclusion criteria in this review and meta-analysis. The quality of included studies ranges from 6.5 to 10 based on the Newcastle-Ottawa quality assessment tool. The pooled prevalence of APP among patients with schizophrenia was 40.6% with 95% confidence interval: 27.6% to 53.7%. Depot first-generation antipsychotics and oral first-generation antipsychotics were the most commonly prescribed APP combinations. Socio-demographic, clinical, and antipsychotic treatment characteristics were significantly associated with APP. There was a wide variation in the correlates of APP assessed by studies and the way that association/correlations was determined and reported. Conclusions: APP is common and highly prevalent. Advanced age, male gender, longer duration of schizophrenia, hospital admission, and longer antipsychotic treatment were correlates of APP in Africa.
引用
收藏
页码:956 / 964
页数:9
相关论文
共 50 条
  • [21] Prevalence of polypharmacy among older adults in Ethiopia: a systematic review and meta-analysis
    Tegene Atamenta kitaw
    Ribka Nigatu Haile
    Scientific Reports, 13
  • [22] Are there socioeconomic inequalities in polypharmacy among older people? A systematic review and meta-analysis
    Anum Iqbal
    Charlotte Richardson
    Zain Iqbal
    Hannah O’Keefe
    Barbara Hanratty
    Fiona E. Matthews
    Adam Todd
    BMC Geriatrics, 23
  • [23] Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis
    Vermeulen, J.
    van Rooijen, G.
    Doedens, P.
    Numminen, E.
    van Tricht, M.
    de Haan, L.
    PSYCHOLOGICAL MEDICINE, 2017, 47 (13) : 2217 - 2228
  • [24] Are there socioeconomic inequalities in polypharmacy among older people? A systematic review and meta-analysis
    Iqbal, A.
    Richardson, C.
    O'Keefe, H.
    Hanratty, B.
    Matthews, F.
    Todd, A.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (06) : 1556 - 1556
  • [25] Prevalence of polypharmacy among older adults in Ethiopia: a systematic review and meta-analysis
    kitaw, Tegene Atamenta
    Haile, Ribka Nigatu
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [26] Are there socioeconomic inequalities in polypharmacy among older people? A systematic review and meta-analysis
    Iqbal, Anum
    Richardson, Charlotte
    Iqbal, Zain
    O'Keefe, Hannah
    Hanratty, Barbara
    Matthews, Fiona E.
    Todd, Adam
    BMC GERIATRICS, 2023, 23 (01)
  • [27] Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews
    Ijaz, Sharea
    Bolea, Blanca
    Davies, Simon
    Savovic, Jelena
    Richards, Alison
    Sullivan, Sarah
    Moran, Paul
    BMC PSYCHIATRY, 2018, 18
  • [28] Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews
    Sharea Ijaz
    Blanca Bolea
    Simon Davies
    Jelena Savović
    Alison Richards
    Sarah Sullivan
    Paul Moran
    BMC Psychiatry, 18
  • [29] Is good insight associated with depression among patients with schizophrenia? Systematic review and meta-analysis
    Murri, Martino Belvederi
    Respino, Matteo
    Innamorati, Marco
    Cervetti, Alice
    Calcagno, Pietro
    Pompili, Maurizio
    Lamis, Dorian A.
    Ghio, Lucio
    Amore, Mario
    SCHIZOPHRENIA RESEARCH, 2015, 162 (1-3) : 234 - 247
  • [30] Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis
    Leucht, Stefan
    Tardy, Magdolna
    Komossa, Katja
    Heres, Stephan
    Kissling, Werner
    Salanti, Georgia
    Davis, John M.
    LANCET, 2012, 379 (9831): : 2063 - 2071